taliglucerase alfa 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5199 37228-64-1

Description:

MoleculeDescription

Synonyms:

  • alfataliglucerase
  • taliglucerase alfa
  • ceramide glucosidase
  • glucocerebrosidase
Taliglucerase alfa, a long term enzyme replacement therapy, is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing the amount of accumulated glucocerebroside. Taliglucerase alfa uptake into cellular lysosomes is mediated by binding of Taliglucerase alfa mannose oligosaccharide chains to specific mannose receptors on the cell surface leading to internalization and subsequent transport to the lysosomes.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
May 1, 2012 FDA PFIZER

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 47.62 34.15 23 486 95879 42524947
Chitotriosidase increased 36.07 34.15 4 505 11 42620815
Drug monitoring procedure not performed 35.79 34.15 6 503 472 42620354

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Inappropriate schedule of product administration 71.08 34.06 38 1222 203599 110384440
Drug monitoring procedure not performed 54.98 34.06 10 1250 1320 110586719

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A16AB11 ALIMENTARY TRACT AND METABOLISM
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
Enzymes
FDA CS M0009360 Glucosylceramidase
FDA EPC N0000175820 Hydrolytic Lysosomal Glucocerebroside-specific Enzyme

Related Drugs by ATC class:

A16AB Enzymes 24 drugs
agalsidase alfaagalsidase betaalglucerasealglucosidase alfaasfotase alfaavalglucosidase alfacerliponase alfacipaglucosidase alfaeladocagene exuparvovecelosulfase alfagalsulfaseidursulfase show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic non-neuropathic Gaucher's disease indication 62201009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
0R4NLX88O4 UNII
4031611 VANDF
C3273401 UMLSCUI
CHEBI:750322 CHEBI
CHEMBL1964120 ChEMBL_ID
DB08876 DRUGBANK_ID
D09675 KEGG_DRUG
9082 INN_ID
C582473 MESH_SUPPLEMENTAL_RECORD_UI
7444 IUPHAR_LIGAND_ID
708713007 SNOMEDCT_US
715566003 SNOMEDCT_US
28522 MMSL
d07867 MMSL
014341 NDDF
1005808-93-4 SECONDARY_CAS_RN
1291609 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ELELYSO HUMAN PRESCRIPTION DRUG LABEL 1 0069-0106 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 200 U INTRAVENOUS BLA 25 sections